Comparing Australian orthopaedic surgeons’ reported use of thromboprophylaxis following arthroplasty in 2012 and 2017 View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Corinne Mirkazemi, Luke R. Bereznicki, Gregory M. Peterson

ABSTRACT

BACKGROUND: It is generally accepted that all arthroplasty patients should receive venous thromboembolism (VTE) and bleeding risk assessments, and that postoperative thromboprophylaxis be routinely prescribed where appropriate. Guideline recommendations regarding what to prescribe, however, have been inconsistent over the years, particularly regarding the appropriateness of aspirin. Our aim was to explore thromboprophylaxis patterns in use following hip and knee arthroplasty in Australia, and to examine associated variables. METHODS: Orthopaedic surgeons were invited via mail to participate in two national surveys, conducted in 2012 (N = 478) and 2017 (N = 820), respectively. RESULTS: The final response rates were 50.0 and 65.8% for 2012 and 2017, respectively. The thromboprophylaxis prescribing routines reported by respondents were divided into four categories: anticoagulant-only (the same anticoagulant-only routine for everyone), aspirin-only (aspirin for everyone), staged-supply (an anticoagulant during the initial postoperative period, followed by aspirin, for everyone) and risk-stratification routines (differing regimens depending on patients' perceived risk of VTE). The most common approaches reported were anticoagulant-only routines; however, their popularity almost halved within the five-year period (from ~ 74% to ~ 41%). Conversely, staged-supply and risk-stratification protocol usage increased by more than two and nine times, respectively. In 2017, over one-half of surgeons reported prescribing aspirin in their practice. Reported concern for postoperative VTE and infections (OR 0.555 95% CI 0.396-0.779, p = 0.001 and OR 1.455 95% CI 1.010-2.097, p = 0.044 respectively), as well as Arthroplasty Society membership (OR 2.814 95% CI 1.367-5.790, p = 0.005) were predictors for use of aspirin (Cox and Snell R square = 0.072). The factor most commonly reported to shape surgeons' protocols was research literature. Factors limiting prescribing of pharmacological prophylaxis included a perception that it increases bleeding and wound infection risk, is inconvenient, and lacks evidence applicable to real-world practice. CONCLUSIONS: VTE prevention post-arthroplasty is an evolving and multi-faceted entity, influenced by a range of factors and seemingly in need of robust evidence from large clinical trials to guide practice. The data highlighted potential short-falls in practice related to aspirin over-use, which could be further explored and addressed in future studies in order to optimise patient outcomes and reduce the significant morbidity and healthcare costs associated with VTE following these increasingly common surgical procedures. More... »

PAGES

57

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12891-019-2409-3

DOI

http://dx.doi.org/10.1186/s12891-019-2409-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112019438

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30736774


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Tasmania", 
          "id": "https://www.grid.ac/institutes/grid.1009.8", 
          "name": [
            "Division of Pharmacy, School of Medicine, University of Tasmania, Private Bag 26, 7001, Hobart, Tasmania, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mirkazemi", 
        "givenName": "Corinne", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Tasmania", 
          "id": "https://www.grid.ac/institutes/grid.1009.8", 
          "name": [
            "Division of Pharmacy, School of Medicine, University of Tasmania, Private Bag 26, 7001, Hobart, Tasmania, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bereznicki", 
        "givenName": "Luke R.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Tasmania", 
          "id": "https://www.grid.ac/institutes/grid.1009.8", 
          "name": [
            "Division of Pharmacy, School of Medicine, University of Tasmania, Private Bag 26, 7001, Hobart, Tasmania, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peterson", 
        "givenName": "Gregory M.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/j.1445-2197.2012.06203.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004773009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1378/chest.08-0656", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019751543"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1378/chest.11-2404", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044700128"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/bja/aew362", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059425363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2106/jbjs.16.00586", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084512160"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2106/jbjs.16.00586", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084512160"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2106/jbjs.16.00586", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084512160"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1712746", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101149193"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: It is generally accepted that all arthroplasty patients should receive venous thromboembolism (VTE) and bleeding risk assessments, and that postoperative thromboprophylaxis be routinely prescribed where appropriate. Guideline recommendations regarding what to prescribe, however, have been inconsistent over the years, particularly regarding the appropriateness of aspirin. Our aim was to explore thromboprophylaxis patterns in use following hip and knee arthroplasty in Australia, and to examine associated variables.\nMETHODS: Orthopaedic surgeons were invited via mail to participate in two national surveys, conducted in 2012 (N\u2009=\u2009478) and 2017 (N\u2009=\u2009820), respectively.\nRESULTS: The final response rates were 50.0 and 65.8% for 2012 and 2017, respectively. The thromboprophylaxis prescribing routines reported by respondents were divided into four categories: anticoagulant-only (the same anticoagulant-only routine for everyone), aspirin-only (aspirin for everyone), staged-supply (an anticoagulant during the initial postoperative period, followed by aspirin, for everyone) and risk-stratification routines (differing regimens depending on patients' perceived\u00a0risk of VTE). The most common approaches reported were anticoagulant-only routines; however, their popularity almost\u00a0halved within the five-year period (from ~\u200974% to ~\u200941%). Conversely, staged-supply and risk-stratification protocol usage increased by more than two and nine times, respectively. In 2017, over one-half of surgeons reported prescribing aspirin in their practice. Reported concern for postoperative VTE and infections (OR 0.555 95% CI 0.396-0.779, p\u2009=\u20090.001 and OR 1.455 95% CI 1.010-2.097, p\u2009=\u20090.044 respectively), as well as Arthroplasty Society membership (OR 2.814 95% CI 1.367-5.790, p\u2009=\u20090.005) were predictors for use of aspirin (Cox and Snell R square\u2009=\u20090.072). The factor most commonly reported to shape surgeons' protocols was research literature. Factors limiting prescribing of pharmacological prophylaxis included a perception that it increases bleeding and wound infection risk, is inconvenient, and lacks evidence applicable to real-world practice.\nCONCLUSIONS: VTE prevention post-arthroplasty is an evolving and multi-faceted entity, influenced by a range of factors and seemingly in need of robust evidence from large clinical trials to guide practice. The data highlighted potential short-falls in practice related to aspirin over-use, which could be further explored and addressed in future studies in order to optimise patient outcomes and reduce the significant morbidity and healthcare costs associated with VTE following these increasingly common surgical procedures.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12891-019-2409-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024957", 
        "issn": [
          "1471-2474"
        ], 
        "name": "BMC Musculoskeletal Disorders", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "name": "Comparing Australian orthopaedic surgeons\u2019 reported use of thromboprophylaxis following arthroplasty in 2012 and 2017", 
    "pagination": "57", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "03a98c23fdf12f5d43e39a557fbc99ec31c9fee24b72c9774bf314b1624feecd"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30736774"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100968565"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12891-019-2409-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112019438"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12891-019-2409-3", 
      "https://app.dimensions.ai/details/publication/pub.1112019438"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000338_0000000338/records_47956_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12891-019-2409-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12891-019-2409-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12891-019-2409-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12891-019-2409-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12891-019-2409-3'


 

This table displays all metadata directly associated to this object as RDF triples.

97 TRIPLES      21 PREDICATES      35 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12891-019-2409-3 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author N58362c52a39742ee8b79d5a8d9d9afb5
4 schema:citation https://doi.org/10.1056/nejmoa1712746
5 https://doi.org/10.1093/bja/aew362
6 https://doi.org/10.1111/j.1445-2197.2012.06203.x
7 https://doi.org/10.1378/chest.08-0656
8 https://doi.org/10.1378/chest.11-2404
9 https://doi.org/10.2106/jbjs.16.00586
10 schema:datePublished 2019-12
11 schema:datePublishedReg 2019-12-01
12 schema:description BACKGROUND: It is generally accepted that all arthroplasty patients should receive venous thromboembolism (VTE) and bleeding risk assessments, and that postoperative thromboprophylaxis be routinely prescribed where appropriate. Guideline recommendations regarding what to prescribe, however, have been inconsistent over the years, particularly regarding the appropriateness of aspirin. Our aim was to explore thromboprophylaxis patterns in use following hip and knee arthroplasty in Australia, and to examine associated variables. METHODS: Orthopaedic surgeons were invited via mail to participate in two national surveys, conducted in 2012 (N = 478) and 2017 (N = 820), respectively. RESULTS: The final response rates were 50.0 and 65.8% for 2012 and 2017, respectively. The thromboprophylaxis prescribing routines reported by respondents were divided into four categories: anticoagulant-only (the same anticoagulant-only routine for everyone), aspirin-only (aspirin for everyone), staged-supply (an anticoagulant during the initial postoperative period, followed by aspirin, for everyone) and risk-stratification routines (differing regimens depending on patients' perceived risk of VTE). The most common approaches reported were anticoagulant-only routines; however, their popularity almost halved within the five-year period (from ~ 74% to ~ 41%). Conversely, staged-supply and risk-stratification protocol usage increased by more than two and nine times, respectively. In 2017, over one-half of surgeons reported prescribing aspirin in their practice. Reported concern for postoperative VTE and infections (OR 0.555 95% CI 0.396-0.779, p = 0.001 and OR 1.455 95% CI 1.010-2.097, p = 0.044 respectively), as well as Arthroplasty Society membership (OR 2.814 95% CI 1.367-5.790, p = 0.005) were predictors for use of aspirin (Cox and Snell R square = 0.072). The factor most commonly reported to shape surgeons' protocols was research literature. Factors limiting prescribing of pharmacological prophylaxis included a perception that it increases bleeding and wound infection risk, is inconvenient, and lacks evidence applicable to real-world practice. CONCLUSIONS: VTE prevention post-arthroplasty is an evolving and multi-faceted entity, influenced by a range of factors and seemingly in need of robust evidence from large clinical trials to guide practice. The data highlighted potential short-falls in practice related to aspirin over-use, which could be further explored and addressed in future studies in order to optimise patient outcomes and reduce the significant morbidity and healthcare costs associated with VTE following these increasingly common surgical procedures.
13 schema:genre research_article
14 schema:inLanguage en
15 schema:isAccessibleForFree true
16 schema:isPartOf N2539949296514ef584b63a6c28899ea4
17 N403c403812db4dc98e8832176387d9c1
18 sg:journal.1024957
19 schema:name Comparing Australian orthopaedic surgeons’ reported use of thromboprophylaxis following arthroplasty in 2012 and 2017
20 schema:pagination 57
21 schema:productId N470f6a22fa824ea0a15e4a6a188bd58b
22 N728e70683d474799b9b119920d5d6a79
23 N99859fcd77bd453ca17bd5c9ef667cd8
24 Nb5823418105148e38adc210fbea2c056
25 Ndb627abe99084a1a9f580ad4ae63c56d
26 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112019438
27 https://doi.org/10.1186/s12891-019-2409-3
28 schema:sdDatePublished 2019-04-11T09:07
29 schema:sdLicense https://scigraph.springernature.com/explorer/license/
30 schema:sdPublisher N54aa28b60bbd4992b8d0a0665a7a061b
31 schema:url https://link.springer.com/10.1186%2Fs12891-019-2409-3
32 sgo:license sg:explorer/license/
33 sgo:sdDataset articles
34 rdf:type schema:ScholarlyArticle
35 N2539949296514ef584b63a6c28899ea4 schema:volumeNumber 20
36 rdf:type schema:PublicationVolume
37 N403c403812db4dc98e8832176387d9c1 schema:issueNumber 1
38 rdf:type schema:PublicationIssue
39 N470f6a22fa824ea0a15e4a6a188bd58b schema:name doi
40 schema:value 10.1186/s12891-019-2409-3
41 rdf:type schema:PropertyValue
42 N4b4273cd225f4f7e9da0dc310980caae schema:affiliation https://www.grid.ac/institutes/grid.1009.8
43 schema:familyName Mirkazemi
44 schema:givenName Corinne
45 rdf:type schema:Person
46 N4c7cf958c14e4161ad8f57cadc3f7979 schema:affiliation https://www.grid.ac/institutes/grid.1009.8
47 schema:familyName Bereznicki
48 schema:givenName Luke R.
49 rdf:type schema:Person
50 N54aa28b60bbd4992b8d0a0665a7a061b schema:name Springer Nature - SN SciGraph project
51 rdf:type schema:Organization
52 N58362c52a39742ee8b79d5a8d9d9afb5 rdf:first N4b4273cd225f4f7e9da0dc310980caae
53 rdf:rest Ndafbad37038d424899e9b72e68f6e3cc
54 N728e70683d474799b9b119920d5d6a79 schema:name readcube_id
55 schema:value 03a98c23fdf12f5d43e39a557fbc99ec31c9fee24b72c9774bf314b1624feecd
56 rdf:type schema:PropertyValue
57 N99859fcd77bd453ca17bd5c9ef667cd8 schema:name dimensions_id
58 schema:value pub.1112019438
59 rdf:type schema:PropertyValue
60 Nb5823418105148e38adc210fbea2c056 schema:name nlm_unique_id
61 schema:value 100968565
62 rdf:type schema:PropertyValue
63 Nd9b685d919ce45b2b260336c6b778867 schema:affiliation https://www.grid.ac/institutes/grid.1009.8
64 schema:familyName Peterson
65 schema:givenName Gregory M.
66 rdf:type schema:Person
67 Ndafbad37038d424899e9b72e68f6e3cc rdf:first N4c7cf958c14e4161ad8f57cadc3f7979
68 rdf:rest Ne0d11e4b94dd4dfbb357cc481682eea0
69 Ndb627abe99084a1a9f580ad4ae63c56d schema:name pubmed_id
70 schema:value 30736774
71 rdf:type schema:PropertyValue
72 Ne0d11e4b94dd4dfbb357cc481682eea0 rdf:first Nd9b685d919ce45b2b260336c6b778867
73 rdf:rest rdf:nil
74 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
75 schema:name Medical and Health Sciences
76 rdf:type schema:DefinedTerm
77 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
78 schema:name Public Health and Health Services
79 rdf:type schema:DefinedTerm
80 sg:journal.1024957 schema:issn 1471-2474
81 schema:name BMC Musculoskeletal Disorders
82 rdf:type schema:Periodical
83 https://doi.org/10.1056/nejmoa1712746 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101149193
84 rdf:type schema:CreativeWork
85 https://doi.org/10.1093/bja/aew362 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059425363
86 rdf:type schema:CreativeWork
87 https://doi.org/10.1111/j.1445-2197.2012.06203.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004773009
88 rdf:type schema:CreativeWork
89 https://doi.org/10.1378/chest.08-0656 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019751543
90 rdf:type schema:CreativeWork
91 https://doi.org/10.1378/chest.11-2404 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044700128
92 rdf:type schema:CreativeWork
93 https://doi.org/10.2106/jbjs.16.00586 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084512160
94 rdf:type schema:CreativeWork
95 https://www.grid.ac/institutes/grid.1009.8 schema:alternateName University of Tasmania
96 schema:name Division of Pharmacy, School of Medicine, University of Tasmania, Private Bag 26, 7001, Hobart, Tasmania, Australia
97 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...